Similar articles

• Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

  Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C. Eichacker PQ, et al. Crit Care Med. 2005 Oct;33(10):2426-8. doi: 10.1097/01.ccm.0000183002.26587.ff. Crit Care Med. 2005. PMID: 16215410 No abstract available.
• Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis.

  Poole D, Bertolini G, Garattini S. Poole D, et al. Lancet Infect Dis. 2009 Jan;9(1):67-72. doi: 10.1016/S1473-3099(08)70306-2. Lancet Infect Dis. 2009. PMID: 19095197
• Risks and benefits of activated protein C treatment for severe sepsis.

  Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Warren HS, et al. N Engl J Med. 2002 Sep 26;347(13):1027-30. doi: 10.1056/NEJMsb020574. N Engl J Med. 2002. PMID: 12324562 No abstract available.
• Use of drotrecogin alfa (activated) in older patients with severe sepsis.

  Alexander SL, Ernst FR. Alexander SL, et al. Pharmacotherapy. 2006 Apr;26(4):533-8. doi: 10.1592/phco.26.4.533. Pharmacotherapy. 2006. PMID: 16553513 Review.
• Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).

  Rudis MI, Fish DN. Rudis MI, et al. Pharmacotherapy. 2002 Dec;22(12 Pt 2):182S-195S. doi: 10.1592/phco.22.18.182s.33704. Pharmacotherapy. 2002. PMID: 12492225 Review.